Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaporization01:18

Vaporization

34.9K
The physical form of a substance changes by changing its temperature. For example, raising the temperature of a liquid causes the liquid to vaporize (convert into vapor). The process is called vaporization—a surface phenomenon. For vaporization to occur, kinetic energy must be greater than the intermolecular forces that keep molecules bonded. The amount of energy needed to vaporize a quantity of liquid at a given pressure and a constant temperature is called the heat of vaporization. When...
34.9K
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

20
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
20
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

16
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

The Journal of urology·2026
Same author

How many traffic fatalities can be attributed to cannabis each year in the US?

The International journal on drug policy·2026
Same author

Prostate Cancer Staging MRI: Prospective Value of Structured Reports With Defined Extraprostatic Extension Grading System.

Journal of computer assisted tomography·2026
Same author

Autoregulation of three yeast ribosomal protein genes by splicing inhibition.

G3 (Bethesda, Md.)·2026
Same author

Clear Cell Renal Cell Carcinoma Involving Intrarenal Adrenal Tissue: A Rare Case With Staging Implications.

Cureus·2026
Same author

Response to Jin et al. (IJDP, 2025, 142, Article 104832): Cannabis consumption and motor vehicle collision: A systematic review and meta-analysis of observational studies.

The International journal on drug policy·2025

Related Experiment Video

Updated: Aug 23, 2025

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K

Transurethral Vapor Ablation in Patients with Intermediate-Risk Localized Prostate Cancer.

Christopher M Dixon1, Richard M Levin2, Christopher H Cantrill3

  • 1WMC Health Good Samaritan Hospital, Bon Secours Urology, Suffern, New York, USA.

Journal of Endourology
|October 31, 2022
PubMed
Summary

Transurethral vapor ablation (TUVA) is a safe and effective treatment for unilateral, intermediate-risk prostate cancer (PCa). This study found TUVA achieved an 87% cancer-free rate on the treated side with minimal side effects and preserved quality of life.

Keywords:
focal ablationminimally invasive surgical therapympMRIprostateprostate cancertransurethral vapor ablation (TUVA)

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.9K
Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.5K

Related Experiment Videos

Last Updated: Aug 23, 2025

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.1K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.9K
Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.5K

Area of Science:

  • Urology
  • Oncology
  • Minimally Invasive Surgery

Background:

  • Localized prostate cancer (PCa) requires effective and minimally invasive treatment options.
  • Unilateral, intermediate-risk PCa presents a specific challenge for treatment planning.
  • Transurethral vapor ablation (TUVA) is an emerging technology for prostate tissue ablation.

Purpose of the Study:

  • To evaluate the safety and efficacy of TUVA for unilateral, intermediate-risk, localized PCa.
  • To assess device-related serious adverse events (SAEs) following TUVA.
  • To determine the oncologic and quality of life outcomes post-TUVA.

Main Methods:

  • Prospective, multicenter, single-arm study of TUVA in men with unilateral, intermediate-risk PCa.
  • Inclusion criteria: age ≥45, biopsy-confirmed unilateral Gleason grade group 2 (GGG2) adenocarcinoma, prostate volume 20-80 cc, PSA ≤15 ng/mL.
  • TUVA delivered via cystoscopy and transrectal ultrasound (TRUS) guidance; outcomes assessed by mpMRI, MRI/TRUS fusion biopsies, and validated QOL questionnaires.

Main Results:

  • No device-related SAEs were reported. Grade 2 AEs included transient urinary retention and temporary sexual dysfunction.
  • At 6 months, 87% of subjects (13/15) had no evidence of ≥GGG2 cancer on the treated side; 67% (10/15) were biopsy-negative.
  • Median prostate volume decreased by 40.7%, PSA by 58%, with no significant negative impact on quality of life.

Conclusions:

  • TUVA is a safe and well-tolerated procedure for men with intermediate-risk, unilateral PCa.
  • Preliminary results demonstrate high rates of cancer eradication and preservation of quality of life.
  • TUVA shows promise as an effective minimally invasive treatment for selected PCa patients.